Javier
Rodríguez Rodríguez
Consultor Médico
Hospital Vall d'Hebron
Barcelona, EspañaPublications in collaboration with researchers from Hospital Vall d'Hebron (6)
2024
-
Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers
British Journal of Surgery, Vol. 111, Núm. 3
2021
-
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 779-789
2020
-
Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients
Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348
2019
-
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)
Scientific Reports
-
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Scientific Reports, Vol. 9, Núm. 1
2005
-
Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: Do we have enough evidence?
World Journal of Gastroenterology